{
    "pmcid": "9020654",
    "qa_pairs": {
        "Against which SARS-CoV-2 variant did DL4 show reduced or no activity?": [
            "Beta, Gamma, Delta, and Omicron variants",
            "Alpha variant",
            "Original Wuhan strain",
            "Lambda variant"
        ],
        "What is the primary target of the nanobody DL4 developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The S2 subunit of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2"
        ],
        "What was the method used to isolate the DL4 nanobody from alpaca lymphocytes?": [
            "Phage display library",
            "Yeast surface display",
            "Hybridoma technology",
            "CRISPR-Cas9 screening"
        ],
        "Which conformational state of the RBD allows for ACE2 binding and is targeted by neutralizing antibodies?": [
            "The 'up' conformation",
            "The 'down' conformation",
            "The 'closed' conformation",
            "The 'open' conformation"
        ],
        "Which mutations were introduced to enhance the neutralizing potency of DL4?": [
            "H56Y, Q101F, and G100E",
            "N501Y, E484K, and K417N",
            "D614G, P681R, and T478K",
            "L452R, T478K, and E484Q"
        ]
    }
}